BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families

@article{Reeves2004BRCA1MI,
  title={BRCA1 mutations in South African breast and/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families},
  author={Michelle Diana Reeves and T M Yawitch and Nerina C. van der Merwe and H J van den Berg and Greta Dreyer and Elizabeth J van Rensburg},
  journal={International Journal of Cancer},
  year={2004},
  volume={110}
}
Germ‐line mutations within BRCA1 are responsible for different proportions of inherited susceptibility to breast/ovarian cancer, and the spectrum of mutations within this gene is often unique to certain populations. At this time, there have been no reports regarding the role of BRCA1 in South African breast and/or ovarian cancer families. We therefore screened 90 South African breast/ovarian cancer families for BRCA1 mutations by means of PCR‐based mutation detection assays. Eighteen families… 
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation
TLDR
It is revealed that LGRs comprise ~3% of identified BRCA1 mutations, a low rate in comparison to other populations, and some of the previously misunderstood rules of nomenclature are clarified, which will make uniform reporting of BRCa1/2 easier in the future.
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
TLDR
The data showed a low prevalence of the BRCA1/2 founder mutations in Colombians of African descent, implying that these mutations should not be recommended for genetic screening programs in the Afro-Colombian population.
Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal
TLDR
This study identified a founder pathogenic variant of BRCA1 predisposing to breast cancer and enabled the establishment of an affordable genetic test as a mean of prevention for Senegalese women at risk of breast cancer.
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
TLDR
BRCA1 5382insC founder mutation is not uncommon among Egyptian FBC females; however, the carrier frequency is lower than those from previous Egyptian studies using different molecular techniques.
Founder mutations in BRCA1 and BRCA2 genes.
  • R. Ferla, V. Caló, +7 authors A. Russo
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
TLDR
The identification of the ethnic group of families undergoing genetic counseling enables the geneticist and oncologist to make more specific choices, leading to simplify the clinical approach to genetic testing carried out on members of high-risk families.
Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
TLDR
Hybridization-based target sequencing of BRCA1/2 in 530 ovarian cancer patients from Henan, the central region of China, followed by haplotype analysis of six short tandem repeat (STR) markers in the patients with recurrent mutations to determine their founder effect was performed, finding the most frequently detected mutation in Henan patients, is a founder mutation in the population.
Breast cancer in high-risk Afrikaner families: Is BRCA founder mutation testing sufficient?
TLDR
BOADICEA is very useful in identifying counsellees at high risk for a BRCA mutation and also assists with the decision to pursue further testing following a negative founder mutation result, and assist in guiding an informed genetic counselling service for at-risk individuals with an Afrikaner background.
New recurring BRCA1 variant: An additional South African founder mutation?
TLDR
It is proposed that the BRCA1 c.45dupT pathogenic variant may be another Afrikaner founder mutation in the SA population, and including this variant in first-line founder mutation screening may reduce testing costs to patients and identify those at risk for HBOC without the need for comprehensive testing.
Molecular Genetic Analysis of Familial Breast Cancer in South Africa
TLDR
The aim of this study was to determine the BRCA1 and BRCa2 mutation spectrum and prevalence in two South African populations, namely Mixed Ancestry and Caucasian, and identify a number of silent polymorphisms as well as variants of unknown functional significance.
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations.
TLDR
Assessing the cancer risk profile in BRCA-mutation-positive and negative South African breast-ovarian cancer families, mainly of Caucasian origin, results can be applied in estimation of cancer risks and may contribute to more comprehensive counselling of mutation-positive Caucasian breast and/or ovarian cancer families.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation
TLDR
Analysis of families with a history of breast and/or ovarian cancer for germline mutations in BRCA1 suggests a transition in risk such that mutations in the 3′ third of the gene are associated with a lower proportion of ovarian cancer.
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
TLDR
An account of familial aggregation in breast/ovarian cancer has become possible with the identification of BRCA1 germ-line mutations and indirect evidence suggests that seven of these mutations are deleterious.
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
TLDR
The high rate of germ-line BRCA1/BRCA2 mutations in Ashkenazi women and families with ovarian cancer is coupled with penetrance that is lower than previously estimated.
BRCA1 mutation analysis in breast/ovarian cancer families from Greece
TLDR
The results show that BRCA1 deleterious mutations are present in a fraction (20%) of Greek breast/ovarian cancer families similar to other European countries.
A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.
TLDR
No specific breast or ovarian cancer phenotype could be assigned to any of the common mutations, and the ovarian cancer incidence among 18 families with the 2804delAA mutation was heterogeneous.
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
TLDR
The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age <50 years.
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
TLDR
A haplotype of nine polymorphic markers within or immediately flanking the BRCA1 locus in a set of 61 breast/ovarian cancer families selected for having one of six recurrent BRCa1 mutations observed a high degree of haplotype conservation across the region.
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
TLDR
The results suggest that one in a hundred women of Ashkenazi descent may be at especially high risk of developing breast and/or ovarian cancer.
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
TLDR
Thirty-seven families with four or more cases of breast cancer or breast and ovarian cancer were analyzed for mutations in BRCA1, and five families of Ashkenazi Jewish descent carried the 185delAG mutation and shared the same haplotype at eight polymorphic markers spanning approximately 850 kb at B RCA1.
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
TLDR
The relatively low frequency of BRCA1 andBRCA2 mutations in the present study could be explained by insufficient screening sensitivity to the location of mutations in uncharacterized regulatory regions, the analysis of phenocopies, or, most likely, within predisposed families, additional un characterized BRCa genes.
...
1
2
3
4
5
...